Purpose: Accurate human epidermal growth factor receptor 2 (HER2) status is important in predicting prognosis and providing treatment for HER2-positive breast cancer patients. However, performing in situ hybridization (ISH) can be an economic burden on developing countries. This study aimed to find an alternative to the ISH test by predicting the HER2 status in patients with equivocal immunohistochemistry (IHC) results. Methods: We retrospectively reviewed the clinical data of 15,535 patients who underwent curative surgery for invasive breast cancer between February 2005 and April 2015 at the Samsung Medical Center. Equivocal HER2 IHC results were obtained for 461 patients. Logistic regression analysis using stepwise selection was performed to identify the clinicopathological factors related to silver in situ hybridization (SISH) status. We analyzed the data by dividing the estrogen receptor and progesterone receptor (PR) into three groups according to Allred score. Results: Multivariable analysis identified poorly differentiated histological grade, lower PR score, higher expression of Ki-67 and p53, and lower expression of cytokeratin 5/6 and epidermal growth factor receptor as predictors of SISH-positive results. The area under the curve for the receiver-operating characteristic curve was 0.74. Conclusion: We identified factors related to a positive HER2 status by SISH. However, there was insufficient power in the prediction model for diagnosis and evaluation. Therefore, the SISH test is essential in determining the HER2 status of breast cancer patients when the IHC result is equivocal.
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Hyun-June Paik, et al. prognosis and providing optimal treatment for HER2-positive breast cancer patients [8] .
The American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network recommend adjuvant chemotherapy with trastuzumab in high-risk HER2-positive disease [9, 10] . The measurement of HER2 usually begins with IHC and progresses to in situ hybridization (ISH) testing if the IHC score is 2+ (equivocal) [11] . Therefore, equivocal IHC results have an important role in optimizing methods to assess HER2 status, since a binary decision must be made regarding target treatments that are potentially beneficial but very expensive and have a risk of cardiotoxicity [11, 12] .
However, ISH methods have some disadvantages. Performing ISH can be an economic burden on a community or patient in developing countries [13] . Additionally, it has been reported that HER2 equivocal cases can result in different HER2 status assessments depending on the ISH assays used and the selection of scoring criteria [14] . Furthermore, chemotherapy can induce an increase in HER2 gene copy numbers, which means that pathologists may have difficulty assessing the HER2 status with the HER2 ISH assay in patients treated with neoadjuvant chemotherapy [15] .
The aim of this study was to analyze factors for silver ISH (SISH)-positive status in breast cancer patients with equivocal IHC results. By identifying these factors, we should be able to predict which patients are able to omit the ISH test when the IHC result is equivocal.
Representative demographic and clinicopathological data were used for the analysis [16] .
METHODS

Patient characteristics
Approval was granted by the Institutional Review Board of the Samsung Medical Center, Seoul, South Korea (IRB file No. 2016-12-138). Patient records and information were anonymized, and identification was removed before analysis to protect personal information.
We retrospectively reviewed the clinical data of 15 [11, 12] . Circumferential membrane staining that was complete, intense, and within >10% of tumor cells was scored "3+." Circumferential membrane staining that was complete and circumferential membrane staining that was intense and within ≤10% of tumor cells or incomplete and/or weak/moderate and within >10% of tumor cells was "2+." Incomplete membrane staining that was faint or barely perceptible and within >10% of tumor cells was "1+." If no staining was observed or membrane staining was incomplete and faint or barely perceptible and within ≤10% of tumor cells, the resulting score was "0."
A score of 3+ was interpreted as positive. An equivocal test was defined as staining with a 2+ score. A score of 0/1+ was interpreted as negative. Before November 2013, the cutoff value of tumor cells was 30% instead of 10%. 
IHC testing for other biomarkers
ER, PR, p53, EGFR, and CK5/6 were analyzed immunohistochemically using antibodies prepared against these proteins. We applied an anti-ER and anti-PR monoclonal antibody to 10% neutral buffered formalin-fixed and paraffin-embedded tissue. Only nuclear staining was scored. Positive staining of ≥1% of tumor cells was defined as a positive test.
p53 IHC staining was performed using an anti-human monoclonal p53 antibody. When assessing each section, nuclear staining >10% was regarded as positive. IHC for EGFR was interpreted as "positive"
or "negative" according to the degree of membrane staining with a cutoff value of 10%. CK5/6 staining was regarded as positive if any membranal and/or cytoplasmic staining was observed. 
Statistical analysis
Statistical analysis was conducted using SAS software version 9.4
(SAS Institute, Cary, USA). Logistic regression analysis was performed to identify clinicopathologic factors related to SISH status. Stepwise selection was used to select predictors for multivariable analysis. The odds ratios (ORs) were estimated with 95% confidence intervals (CIs).
Statistical significance was set at p < 0.05. A receiver-operating characteristic (ROC) curve was analyzed to evaluate the models in this study [17] . ER and PR statuses were categorized into low, intermediate, and 
RESULTS
Overall
DISCUSSION
IHC is much easier to perform than ISH and is generally less expensive in many countries [13, 18] . Most pathology laboratories can perform IHC without external help or resources. In contrast, only specialized laboratories are able to perform ISH because of the specialized equipment and training required [18] . Furthermore, the cost of the ISH test is 2 to 4 times higher than that of IHC [13] . For this reason, many surgical pathology laboratories first measure HER2 using IHC and progress to ISH testing only if IHC is equivocal [19] .
In October 2013, ASCO and CAP updated the guidelines issued in January 2007 for HER2 testing in breast cancer [11, 12] This change in ASCO/CAP guidelines for HER2 testing increases the proportion of reflex ISH tests and HER2-positive breast cancers [20] .
Although a combination of IHC and ISH is the current standard method to measure HER2 status, it is not an absolute method to detect HER2 expression. IHC results can change depending on antibodies, fixatives, and technical assessment. IHC staining is easy to perform and relatively inexpensive to detect HER2 status; however, the results are ambiguous because they show inter-and intra-laboratory variability in sensitivity and specificity [21] . Moreover, HER2 status assessment can differ depending on the ISH assays used and the selection of scoring criteria [14] . In addition, an increase in HER2 gene copy numbers can be induced by chemotherapy, which means accurately assessing HER2 status in patients treated with neoadjuvant chemotherapy may be challenging for pathologists [15] . DISH slides is superior to HER2 FISH slides and tissue morphology assessment is easier than on chromogenic assays [22] . Real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) is currently being tested as a method for measuring HER2 status. The RT-qPCR method detects HER2 status at the level of gene copy number and relative messenger RNA expression. This fast, simple, and quantitative approach provides a viable alternative for the evaluation of HER2 gene alteration in routine clinical practice [21] .
In the present study, we focused on predicting patients who could omit the ISH test when their IHC results were equivocal. We found In this study, ER and PR showed contradictory results in predicting HER2 status before and after categorizing ER and PR into three groups according to Allred score. This is probably because the ER and PR Allred scores of patients were not evenly distributed between 0 and 8. Most patients had scores of 7 or 8, which corresponds to the "high"
group. In this study, 69.9% (ER) and 48.8% (PR) of the total patients were in the "high" group.
In previous studies from our group, ER, PR, HER2, Ki-67, p53, CK5/6, and EGFR were routinely checked at our center [23, 24] . p53 is a tumor-suppressor gene that can induce apoptosis after DNA damage [25] . p53 overexpression has been found to be related to aggressive features of breast cancer, and the prognostic significance of p53 overexpression has been reported in other studies [24] . p53 mutations can lead to a loss of function of the p63 gene that causes amplification of the EGFR gene [26] . EGFR can promote tumor cell migration and is associated with tumor aggressiveness [23] . Overexpression of EGFR in HER2-positive breast cancer is a poor prognostic factor but it is a predictive factor for trastuzumab response [27] . Expression of either EGFR or CK5/6 has been reported to accurately identify a basal-like subtype of breast cancer [4] .
When IHC results are equivocal, the HER2 positive rate by ISH is known to be approximately 30% [28] . In our study, the HER2 positive rate was approximately 40%. We considered that this difference might be because a large proportion of patients involved in our research were evaluated using the 2013 ASCO/CAP guideline [11] , and that SISH was the method of ISH rather than FISH [29] .
In this study, we identified factors related to an HER2-positive status by SISH when the IHC result was equivocal. The AUC for ROC was improved when p53, CK5/6, and EGFR were analyzed together 
